Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep:6:1428-1438.
doi: 10.1200/GO.20.00351.

Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study

Affiliations

Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study

Abdul Rahman Jazieh et al. JCO Glob Oncol. 2020 Sep.

Abstract

Purpose: The COVID-19 pandemic affected health care systems globally and resulted in the interruption of usual care in many health care facilities, exposing vulnerable patients with cancer to significant risks. Our study aimed to evaluate the impact of this pandemic on cancer care worldwide.

Methods: We conducted a cross-sectional study using a validated web-based questionnaire of 51 items. The questionnaire obtained information on the capacity and services offered at these centers, magnitude of disruption of care, reasons for disruption, challenges faced, interventions implemented, and the estimation of patient harm during the pandemic.

Results: A total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Missing at least one cycle of therapy by > 10% of patients was reported in 46.31% of the centers. Participants reported patient exposure to harm from interruption of cancer-specific care (36.52%) and noncancer-related care (39.04%), with some centers estimating that up to 80% of their patients were exposed to harm.

Conclusion: The detrimental impact of the COVID-19 pandemic on cancer care is widespread, with varying magnitude among centers worldwide. Additional research to assess this impact at the patient level is required.

PubMed Disclaimer

Conflict of interest statement

Abdul Rahman Jazieh

Research Funding: MSD Oncology

Travel, Accommodations, Expenses: AstraZeneca, Bristol Myers Squibb

Giuseppe Curigliano

Honoraria: Ellipses Pharma

Consulting or Advisory Role: Roche, Genentech, Pfizer, Novartis, Eli Lilly, Foundation Medicine, Bristol Myers Squibb, Samsung, AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim, GlaxoSmithKline, Seattle Genetics

Speakers’ Bureau: Roche, Genentech, Novartis, Pfizer, Eli Lilly, Foundation Medicine, Samsung, Daiichi Sankyo

Research Funding: Merck (Inst)

Travel, Accommodations, Expenses: Roche, Genentech, Pfizer

Evangelia D. Razis

Consulting or Advisory Role: AstraZeneca, Bristol Myers Squibb, Pfizer

Research Funding: Novartis, Demo Pharmaceutical, Celldex, PAREXEL, Tesaro, Anabiosis Pharmaceuticals, Radius Health

Travel, Accommodations, Expenses: Genesis Pharmaceuticals, LEO Pharma, Roche, Genekor, Merck, Ipsen, Sanofi

Hassan Errihani

Consulting or Advisory Role: Pfizer, Roche, MSD, Merck

Speakers’ Bureau: Novartis, Amgen

Research Funding: Roche

Travel, Accommodations, Expenses: Pierre Fabre (Inst), Merck (Inst)

Roselle B. De Guzman

Honoraria: Roche Oncology (Philippines), AstraZeneca, Novartis, Merck Serono, MSD Oncology, Boehringer Ingelheim

Consulting or Advisory Role: Roche, Novartis, Boehringer Ingelheim, AstraZeneca, Centus Biotherapeutics

Travel, Accommodations, Expenses: Hospira (Philippines), Roche (Philippines), Merck Sharp & Dohme, Eisai, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis

Christian Rolfo

Consulting or Advisory Role: Mylan, Archer Biosciences, Oncompass, Inivata, Merck Serono

Speakers’ Bureau: Novartis, MSD, Boehringer Ingelheim, Guardant Health, AstraZeneca

Research Funding: Lung Cancer Research Foundation, Pfizer

Travel, Accommodations, Expenses: AstraZeneca

Uncompensated Relationships: OncoDNA, Biomark, Guardant Health,

No other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Number of the participating centers per country.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018 [Erratum: CA Cancer J Clin 70:313, 2020] - PubMed
    1. Silbermann M, Pitsillides B, Al-Alfi N, et al. Multidisciplinary care team for cancer patients and its implementation in several Middle Eastern countries. Ann Oncol. 2013;24:vii41–vii47. - PMC - PubMed
    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207. - PMC - PubMed
    1. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924. - PMC - PubMed
    1. World Health Organization: WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re....

MeSH terms